EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY-NC 4.0

Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility Post-Approval Study

Tim R Betts iD, Marek Grygier iD, Jens Erik Nielsen Kudsk iD, Thomas Schmitz, Marcus Sandri, Gavino Casu iD, Martin Bergmann iD, David Hildick-Smith iD, Thomas Christen, Dominic J Allocco iD, FLXibility investigators

EP Europace · 2023

DOI: 10.1093/europace/euac270 ↗

Kurz gefasst

Kommentar in der Zeitschrift EP Europace, 2023. Verfasst von Tim R Betts und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Oxford University Hospitals NHS Trust, Headley Way, Oxford OX3 9DU, UK. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Stroke. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Boston Scientific Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

The FLXibility Post-Approval Study collected data on unselected patients implanted with a WATCHMAN FLX in a commercial clinical setting. Methods and results Patients were implanted with a WATCHMAN FLX per local standard of care, with a subsequent first follow-up visit from 45 to 120 days post-implant and a final follow-up at 1-year post-procedure. A Clinical Event Committee adjudicated all major adverse events and TEE/CT imaging results were adjudicated by a core laboratory. Among 300 patients enrolled at 17 centres in Europe, the mean age was 74.6 ± 8.0 years, mean CHA2DS2-VASc score was 4.3 ± 1.6, and 62.1% were male. The device was successfully implanted in 99.0% (297/300) of patients. The post-implant medication regimen was DAPT for 87.3% (262/300). At first follow-up, core-lab adjudicated complete seal was 88.2% (149/169), 9.5% (16/169) had leak <3 mm, 2.4 (4/169) had leak ≥3 mm to ≤5 mm, and 0% had >5 mm leak. At 1 year, 93.3% (280/300) had final follow-up; 60.5% of patients were on a single antiplatelet medication, 21.4% were on DAPT, 5.6% were on direct oral anticoagulation, and 12.1% were not taking any antiplatelet/anticoagulation medication. Adverse event rates through 1 year were: all-cause death 10.8% (32/295); CV/unexplained death 5.1% (15/295); disabling and non-disabling stroke each 1.0% (3/295, all non-fatal); pericardial effusion requiring surgery or pericardiocentesis 1.0% (3/295); and device-related thrombus 2.4% (7/295).

Conclusion

The WATCHMAN FLX device had excellent procedural success rates, high LAA seal rates, and low rates of thromboembolic events in everyday clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial AppendageAtrial FibrillationStrokeHumansMaleAgedAged, 80 and overFemalePlatelet Aggregation InhibitorsTreatment OutcomeAnticoagulantsCardiac CatheterizationEchocardiography, Transesophageal

Stichwörter der Autor:innen

Atrial fibrillationLeft atrial appendage closureLeft atrial appendage obstructionStroke prevention (limit 6)WATCHMAN FLX

Substanzen

Platelet Aggregation InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Department of Cardiology, Oxford University Hospitals NHS Trust, Headley Way, Oxford OX3 9DU, UK.
  • Chair and First Department of Cardiology, Poznan University School of Medical Sciences, Długa 1/2, 61-848 Poznan, Poland.
  • Department of Cardiology, Aarhus University Hospital, Palle Juul-Jensens Boulevard 69, 8200 Aarhus N, Denmark.
  • Department of Cardiology, Elisabeth-Krankenhaus-Essen GmbH, 45138 Essen, Germany.
  • Department of Internal Medicine/Cardiology, University of Leipzig, Heart Centre, Strümpellstraße 39, 04289 Leipzig, Germany.
  • Cardiologia Clinica e Interventistica, Azienda Ospedaliero Universitaria di Sassari, Sassari 07100, Italy.

ORCID-Profile: Tim R Betts, Marek Grygier, Jens Erik Nielsen Kudsk, Gavino Casu, Martin Bergmann, David Hildick-Smith, Dominic J Allocco

Förderung

  • Boston Scientific Corporation

Zitieren

APA

Betts, T. R., Grygier, M., Nielsen Kudsk, J. E., Schmitz, T., Sandri, M., Casu, G., Bergmann, M., Hildick-Smith, D., Christen, T., Allocco, D. J., & FLXibility investigators (2023). Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility Post-Approval Study. EP Europace. https://doi.org/10.1093/europace/euac270

Vancouver

Betts TR, Grygier M, Nielsen Kudsk JE, Schmitz T, Sandri M, Casu G, et al. Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility Post-Approval Study. EP Europace. 2023. doi:10.1093/europace/euac270

BibTeX
@article{Betts2023,
  author = {Betts, Tim R and Grygier, Marek and Nielsen Kudsk, Jens Erik and Schmitz, Thomas and Sandri, Marcus and Casu, Gavino and Bergmann, Martin and Hildick-Smith, David and Christen, Thomas and Allocco, Dominic J and FLXibility investigators, FLXibility investigators},
  title = {Real-world clinical outcomes with a next-generation left atrial appendage closure device: the FLXibility Post-Approval Study},
  journal = {EP Europace},
  year = {2023},
  doi = {10.1093/europace/euac270}
}
Kostenlos starten →